**Table 1.** Tumor status during the 2-year observation period by age

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Tumor status  at Baseline, n (%)** | **Within 1st year (including Baseline) N=176** | | | **Within 2nd year N=173** | | |
| **<40 years n=78** | **40–59 years n=69** | **≥60 years n=29** | **<40 years n=75** | **40–59 years n=69** | **≥60 years n=29** |
| Naïve (no prior treatment) | 13 (16.7) | 10 (14.5) | 5 (17.2) | 12 (16.0) | 10 (14.5) | 5 (17.2) |
| Primary diagnosis and at least one prior treatment\* | 28 (35.9) | 29 (42.0) | 13 (44.8) | 27 (36.0) | 29 (42.0) | 13 (44.8) |
| Recurrent disease and at least one prior treatment\* | 37 (47.4) | 30 (43.5) | 11 (37.9) | 36 (48.0) | 30 (43.5) | 11 (37.9) |

\*Prior treatments included: Only Surgery, Only Systemic Treatment (pexidartinib, imatinib, nilotinib, investigator study medicine), Surgery + Other Treatment (radiotherapy or 90Yttrium, or systemic treatment), and Other Treatment (radiotherapy or 90Yttrium).